US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties
Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to...
CRO / CMO / CDMO
Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production
Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...
Shenzhen Hepalink Reports 2023 Revenue Dip Amid Sector Demand Declines
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China,...
WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer
WuXi AppTec (SHA: 603259, HKG: 2359), a leading Contract Research, Development, and Manufacturing Organization (CRDMO)...
FDA Reviews Eisai’s Leqembi for Expanded Use as Monthly Alzheimer’s Therapy
The US Food and Drug Administration (FDA) has given the green light to review an...
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into...
WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions
WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups
China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science...
WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...
OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in...
VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology
VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation
Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has...
WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles
WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results...
CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...
VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions
VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership...
Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...
WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG:...
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...